Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000516442 | SCV000614649 | uncertain significance | not specified | 2016-10-27 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000727425 | SCV000708449 | uncertain significance | not provided | 2017-05-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002060252 | SCV002419481 | likely benign | Epidermolysis bullosa simplex 5B, with muscular dystrophy; Epidermolysis bullosa simplex, Ogna type; Epidermolysis bullosa simplex 5C, with pyloric atresia; Autosomal recessive limb-girdle muscular dystrophy type 2Q; Epidermolysis bullosa simplex with nail dystrophy | 2021-08-31 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000727425 | SCV003809085 | uncertain significance | not provided | 2019-07-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003159661 | SCV003882887 | uncertain significance | Inborn genetic diseases | 2023-02-27 | criteria provided, single submitter | clinical testing | The c.6347C>T (p.A2116V) alteration is located in exon 32 (coding exon 31) of the PLEC gene. This alteration results from a C to T substitution at nucleotide position 6347, causing the alanine (A) at amino acid position 2116 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |